This is a preview of subscription content, log in via an institution to check access.
Reference
Wan XM, et al. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. Cancer : 9 Jul 2019. Available from: URL: https://doi.org/10.1002/cncr.32368
Rights and permissions
About this article
Cite this article
Adding atezolizumab improves survival in lung cancer at high cost. PharmacoEcon Outcomes News 833, 5 (2019). https://doi.org/10.1007/s40274-019-6069-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6069-1